BioForge Phase III — Trial Design Under FDA & EMA

Architect a Phase III oncology trial for BFG-722 (HER2-mt NSCLC) that satisfies FDA accelerated-approval, EMA centralised, and IDMC charter standards under a 9-12 month competitor lead. Three rounds: trial design, FDA+EMA dialog, IDMC charter and strategic-pivot memo.